

Alvina Dor-Yan Chu

Adjunct Clinical Assistant Professor, Medicine - Immunology & Rheumatology

CLINICAL OFFICE (PRIMARY)

- **Immunology and Rheumatology Clinic**

900 Blake Wilbur Dr Rm W2081

2nd Fl

Stanford, CA 94305

Tel (650) 723-6961 **Fax** (650) 723-3059

Bio

BIO

Alvina Chu, MD, is an adjunct clinical faculty member within the Division of Immunology and Rheumatology. She has practiced rheumatology for more than 10 years, specializing in treatment of a wide range of chronic inflammatory conditions including rheumatoid arthritis, lupus, vasculitis, and gout.

She holds a longstanding scientific interest in immunology, especially the role of B-cell signaling mechanisms in lupus and other autoimmune diseases.

In addition to taking care of patients in clinic and in the hospital, Dr. Chu enjoys teaching and mentoring fellows, residents, and medical students.

CLINICAL FOCUS

- Rheumatology

PROFESSIONAL EDUCATION

- Residency: University of Chicago Hospitals Internal Medicine Residency (2005) IL
- Fellowship: Stanford University Rheumatology and Immunology Fellowship (2007) CA
- Board Certification: Rheumatology, American Board of Internal Medicine (2018)
- Medical Education: State University of New York - Buffalo (2002) NY

Publications

PUBLICATIONS

- **Upadacitinib in Active Ankylosing Spondylitis: 1-Year Results From the Double-Blind, Placebo-Controlled SELECT-AXIS 1 Study and Open-Label Extension.** *Arthritis & rheumatology (Hoboken, N.J.)*
Deodhar, A., van der Heijde, D., Sieper, J., Van den Bosch, F., Maksymowych, W. P., Kim, T. H., Kishimoto, M., Ostor, A., Combe, B., Sui, Y., Chu, A. D., Song, I. H.
2021
- **Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.** *Lancet (London, England)*
Reich, K., Teixeira, H. D., de Bruin-Weller, M., Bieber, T., Soong, W., Kabashima, K., Werfel, T., Zeng, J., Huang, X., Hu, X., Hendrickson, B. A., Ladizinski, B., Chu, et al
2021; 397 (10290): 2169-2181

- **Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.** *Lancet (London, England)*
Guttman-Yassky, E., Teixeira, H. D., Simpson, E. L., Papp, K. A., Pangan, A. L., Blauvelt, A., Thaçi, D., Chu, C. Y., Hong, H. C., Katoh, N., Paller, A. S., Calimlim, B., Gu, et al
2021; 397 (10290): 2151-2168
- **Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.** *Lancet (London, England)*
van der Heijde, D., Song, I. H., Pangan, A. L., Deodhar, A., van den Bosch, F., Maksymowych, W. P., Kim, T. H., Kishimoto, M., Everding, A., Sui, Y., Wang, X., Chu, A. D., Sieper, et al
2019; 394 (10214): 2108-2117
- **Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials** *BRITISH JOURNAL OF HAEMATOLOGY*
Jones, J., Mato, A., Coutre, S., Byrd, J. C., Furman, R. R., Hillmen, P., Osterborg, A., Tam, C., Stilgenbauer, S., Wierda, W. G., Heerema, N. A., Eckert, K., Clow, et al
2018; 182 (4): 504–12
- **Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia A Pooled Analysis of 2 Clinical Trials** *JAMA ONCOLOGY*
O'Brien, S. M., Jaglowski, S., Byrd, J. C., Bannerji, R., Blum, K. A., Fox, C. P., Furman, R. R., Hillmen, P., Kipps, T. J., Montillo, M., Sharman, J., Suzuki, S., James, et al
2018; 4 (5): 712–16
- **Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience** *BLOOD*
O'Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., Heerema, N. A., Johnson, A. J., Luan, et al
2018; 131 (17): 1910–19
- **Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study** *LANCET ONCOLOGY*
O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M. J., Call, et al
2016; 17 (10): 1409-1418
- **Development of Th17-Associated Interstitial Kidney Inflammation in Lupus-Prone Mice Lacking the Gene Encoding STAT-1** *ARTHRITIS & RHEUMATOLOGY*
Yiu, G., Rasmussen, T. K., Ajami, B., Haddon, D. J., Chu, A. D., Tangsombatvisit, S., Haynes, W. A., Diep, V., Steinman, L., Faix, J., Utz, P. J.
2016; 68 (5): 1233-1244
- **A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study** *ANNALS OF THE RHEUMATIC DISEASES*
Furie, R. A., LEON, G., Thomas, M., Petri, M. A., Chu, A. D., Hislop, C., Martin, R. S., Scheinberg, M. A.
2015; 74 (9): 1667-1675
- **Tetramers reveal IL-17-secreting CD4+ T cells that are specific for U1-70 in lupus and mixed connective tissue disease.** *Proceedings of the National Academy of Sciences of the United States of America*
Kattah, N. H., Newell, E. W., Jarrell, J. A., Chu, A. D., Xie, J., Kattah, M. G., Goldberger, O., Ye, J., Chakravarty, E. F., Davis, M. M., Utz, P. J.
2015; 112 (10): 3044-3049
- **Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.** *New England journal of medicine*
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., Devereux, S., Barr, P. M., Furman, et al
2014; 371 (3): 213-223
- **Assessing disease activity and outcome in systemic lupus erythematosus** *Rheumatology*
Strand, V., Chu, A. D.
Elsevier.2014; 6
- **B-cell kinase inhibitors in rheumatoid arthritis** *Open Access Arthritis*
Chu, A. D., Chang, B. Y.

2013; 1 (2): 17

- **Design of clinical trials in rheumatology** *Oxford Textbook of Rheumatology*
Strand, V., Sokolove, J., Chu, A. D.
Oxford University Press.2013; 4
- **Generic Versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus** *JOURNAL OF RHEUMATOLOGY*
Strand, V., Chu, A. D.
2011; 38 (9): 1821-1823
- **Measuring outcomes in systemic lupus erythematosus clinical trials** *EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH*
Strand, V., Chu, A. D.
2011; 11 (4): 455-468
- **Natural Killer Cells From Children With Type 1 Diabetes Have Defects in NKG2D-Dependent Function and Signaling** *DIABETES*
Qin, H., Lee, I., Panagiotopoulos, C., Wang, X., Chu, A. D., Utz, P. J., Priatel, J. J., Tan, R.
2011; 60 (3): 857-866
- **Active and Latent Tuberculosis in Patients With Systemic Lupus Erythematosus Living in the United States** *JCR-JOURNAL OF CLINICAL RHEUMATOLOGY*
Chu, A. D., Polesky, A. H., Bhatia, G., Bush, T. M.
2009; 15 (5): 226-229
- **IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice** *JOURNAL OF CLINICAL INVESTIGATION*
Thibault, D. L., Chu, A. D., Graham, K. L., Balboni, I., Lee, L. Y., Kohlmoos, C., Landrigan, A., Higgins, J. P., Tibshirani, R., Utz, P. J.
2008; 118 (4): 1417-1426
- **Tissue specificity of E- and P-selectin ligands in Th1-mediated chronic inflammation** *JOURNAL OF IMMUNOLOGY*
Chu, A., Hong, K., BERG, E. L., Ehrhardt, R. O.
1999; 163 (9): 5086-5093
- **IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder** *JOURNAL OF IMMUNOLOGY*
Hong, K., Chu, A., Ludviksson, B. R., BERG, E. L., Ehrhardt, R. O.
1999; 162 (12): 7480-7491